Sight Sciences (SGHT) Common Equity (2020 - 2026)
Sight Sciences has reported Common Equity over the past 6 years, most recently at $63.9 million for Q4 2025.
- For Q4 2025, Common Equity fell 26.94% year-over-year to $63.9 million; the TTM value through Dec 2025 reached $63.9 million, down 26.94%, while the annual FY2025 figure was $63.9 million, 26.94% down from the prior year.
- Common Equity for Q4 2025 was $63.9 million at Sight Sciences, down from $64.3 million in the prior quarter.
- Over five years, Common Equity peaked at $232.1 million in Q4 2021 and troughed at -$246.0 million in Q3 2021.
- A 5-year average of $85.2 million and a median of $105.4 million in 2024 define the central range for Common Equity.
- On a YoY basis, Common Equity climbed as much as 361.24% in 2021 and fell as far as 207.62% in 2021.
- Year by year, Common Equity stood at $232.1 million in 2021, then tumbled by 31.03% to $160.1 million in 2022, then dropped by 24.9% to $120.2 million in 2023, then dropped by 27.19% to $87.5 million in 2024, then fell by 26.94% to $63.9 million in 2025.
- Business Quant data shows Common Equity for SGHT at $63.9 million in Q4 2025, $64.3 million in Q3 2025, and $70.0 million in Q2 2025.